Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

NNC0519-0130

Stage Phase 2Stale

Sponsor Novo Nordisk A/S

Route oral and injection

Sources

registry, as of 2026-03-11Stale

https://clinicaltrials.gov/study/NCT06717698

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease. Overall status RECRUITING. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 465. Conditions Chronic Kidney Disease. The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participant

ClinicalTrials.gov NCT06717698 protocol and results modules

registry, as of 2025-12-31Stale

https://clinicaltrials.gov/study/NCT05363774

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 161. Conditions Healthy Volunteers (Diabetes Mellitus, Type 2). NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite. This could help reducing overweight which is often present in participants with type

ClinicalTrials.gov NCT05363774 protocol and results modules

registry, as of 2026-04-03Stale

https://clinicaltrials.gov/study/NCT06718998

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 134. Conditions Obesity. Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and people with excess body weight. This study will look at the safety and tolerability of NNC0519-0130. The purpose of this study is to investigat

ClinicalTrials.gov NCT06718998 protocol and results modules

registry, as of 2025-12-31Stale

https://clinicaltrials.gov/study/NCT06567041

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 82. Conditions Diabetes Mellitus, Type 2; Obesity. A new study medicine called NNC0519-0130 to improve treatment options for people living with excess body weight, with or without type 2 diabetes. The purpose of the study is to investigate potential side effects and blood levels of NNC0519-0130, as well as changes in body weight,

ClinicalTrials.gov NCT06567041 protocol and results modules

registry, as of 2025-11-25Stale

https://clinicaltrials.gov/study/NCT06642571

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 46. Conditions Obesity. This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both. The purpose of this study is to compare the amount of NNC0519-0130 in the blood of participants who have excess

ClinicalTrials.gov NCT06642571 protocol and results modules

registry, as of 2026-03-31Stale

https://clinicaltrials.gov/study/NCT07004322

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 20. Conditions Diabetes Mellitus, Type 2; Obesity. Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight. In this study, the concentration of NNC0519-0130 in the blood will be measured and its safety will be evaluated. The partic

ClinicalTrials.gov NCT07004322 protocol and results modules

Studies

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Registry NCT06717698

Phase Phase 2

Status Recruiting

Enrollment 465

Start 2024-12-02

Primary completion 2026-09-01

Study completion 2026-09-17

Catalyst Primary completion. 2026-09-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Dosing scheme a: NNC0519-0130

Regimen once weekly

Weeks 43

Comparator placebo

Population Chronic Kidney Disease

Dosing scheme a: Placebo

Regimen once weekly

Weeks 43

Population Chronic Kidney Disease

Dosing scheme b: NNC0519-0130

Regimen once weekly

Weeks 43

Comparator placebo

Population Chronic Kidney Disease

Dosing scheme b: Placebo

Regimen once weekly

Weeks 43

Population Chronic Kidney Disease

Dosing scheme c: NNC0519-0130

Regimen once weekly

Weeks 43

Comparator placebo

Population Chronic Kidney Disease

Dosing scheme c: Placebo

Regimen once weekly

Weeks 43

Population Chronic Kidney Disease

Dosing scheme d: NNC0519-0130

Regimen once weekly

Weeks 43

Comparator placebo

Population Chronic Kidney Disease

Dosing scheme d: Placebo

Regimen once weekly

Weeks 43

Population Chronic Kidney Disease

Dosing scheme e: Semaglutide

Regimen once weekly

Weeks 43

Comparator placebo

Population Chronic Kidney Disease

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Registry NCT05363774

EudraCT 2021-004856-41

Phase Phase 1

Status Completed

Enrollment 161

Start 2022-04-20

Primary completion 2024-04-02

Study completion 2024-04-02

Single ascending dose (SAD) part

Regimen once weekly

Weeks 18

Population Healthy Volunteers (Diabetes Mellitus, Type 2)

Multiple ascending dose (MAD) QD part

Regimen once weekly

Weeks 18

Population Healthy Volunteers (Diabetes Mellitus, Type 2)

Type 2 diabetes (T2D) part

Regimen once weekly

Weeks 18

Population Healthy Volunteers (Diabetes Mellitus, Type 2)

MAD QW part

Regimen once weekly

Weeks 18

Population Healthy Volunteers (Diabetes Mellitus, Type 2)

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity

Registry NCT06718998

Phase Phase 1

Status Completed

Enrollment 134

Start 2024-11-20

Primary completion 2026-01-12

Study completion 2026-01-12

Catalyst Primary completion. 2026-01-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: NNC0519-0130

Regimen once weekly

Weeks 24

Population Obesity

Arm 2: NNC0519-0130

Regimen once weekly

Weeks 24

Population Obesity

Arm 3: NNC0519-0130

Regimen weekly

Weeks 24

Population Obesity

Arm 4: NNC0519-0130

Regimen once weekly

Weeks 24

Population Obesity

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes

Registry NCT06567041

Phase Phase 1

Status Completed

Enrollment 82

Start 2024-08-07

Primary completion 2025-12-10

Study completion 2025-12-10

Catalyst Primary completion. 2025-12-10. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

NNC0519-0130

Regimen once weekly

Weeks 37

Comparator placebo

Population Diabetes Mellitus, Type 2; Obesity

Placebo

Regimen once weekly

Weeks 37

Population Diabetes Mellitus, Type 2; Obesity

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

Registry NCT06642571

Phase Phase 1

Status Completed

Enrollment 46

Start 2024-10-15

Primary completion 2025-05-17

Study completion 2025-05-31

Catalyst Primary completion. 2025-05-17. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part 1a: NNC0519-0130 C and NNC0519-0130 B

Population Obesity

Part 1b: NNC0519-0130 B and NNC0519-0130 C

Population Obesity

Part 2a: NNC0519-0130 B and NNC0519-0130 C

Population Obesity

Part 2b: NNC0519-0130 C and NNC0519-0130 B

Population Obesity

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

Registry NCT07004322

Phase Phase 1

Status Completed

Enrollment 20

Start 2025-05-26

Primary completion 2026-01-28

Study completion 2026-01-28

Catalyst Primary completion. 2026-01-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

NNC0519-0130

Regimen once weekly

Weeks 28

Comparator placebo

Population Diabetes Mellitus, Type 2; Obesity

Placebo

Regimen once weekly

Weeks 28

Population Diabetes Mellitus, Type 2; Obesity